Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Key Points
patient
Guidance for Bone Marrow Failure Patients to Protect Against Coronavirus (COVID-19)
This content has been prepared in consultation with AAMDSIF Medical Advisory Board Chair Mikkael Sekeres MD, MS of Sylvester Comprehensive Cancer Center, University of Miami and Co-Chair Olatoyosi Odenike MD of the University of Chicago with additional review by Amy DeZern, MD, Johns Hopkins and Carlos De Castro, MD, Duke. ( November 2022)
“Everything is going to be okay:” Jocelyn’s Story of Aplastic Anemia, PNH, and Survivorship
Person's Name:
Jocelyn Boyer
Before diagnosis, Jocelyn’s life was normal, predictable. She was thriving her senior year in college, studying Public Relations. In 2008, she was working, volunteering, attending classes---all the normal activities for a 20-year-old.
But one day that changed. Extreme fatigue set in, making it difficult to walk a single flight of stairs. At first, she dismissed the fatigue to her rigorous schedule.
Bone Marrow Disease(s):
Content source:
AAMDSIF Podcast for Patients: Dr. Yacoub explains MDS/MPN Overlap Diagnosis and Treatment
Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPN overlap. He includes how molecular testing is used in determining treatment options.
He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.
AAMDSIF Podcast for Patients: Dr. Amit Verma discusses approval of Luspatercept for certain MDS patients
Here is a discussion of the recent approval of Luspatercept with Dr. Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. He explains the results of clinical trials and describes which MDS patients have the best response to this medication.
#MDS #treatingMDS
Luspatercept-aamt
AAMDSIF Podcast for Patients: Dr. Gustavo Rivero discusses Low-Risk MDS
Dr. Gustavo Rivero describes strategies for the management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.
Dr. Vu Duong explains High-Risk and Low-Risk MDS
Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.
MDS to AML, treatment and options with Dr. Tiffany Tanaka, UC San Diego
Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.
Eliot thrives after transplant and clinical trial for MDS - AML
Eliot's disease of Myelodysplastic Syndromes with IDH1 and IDH2 mutations developed quickly. His son was his donor for the haploidentical bone marrow transplant, and now he thrives thanks to a clinical trial drug that keeps the Acute Myeloid Leukemia and MDS in remission. Listen to his story now.